The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients

Journal of Cardiovascular Medicine

Volumn 8, Issue 6, 2007, Pages 453-456

  Goldhammer, Ehud ^a   Maor, Irit ^a   Shnitzer, Sergei ^a   Lanir, Amos ^a   Abinader, Edward G ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Anti oxidant; Carvedilol; Congestive heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; OXYGEN RADICAL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; MORTALITY; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; THERMOLUMINESCENCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; PROPANOLAMINES; REACTIVE OXYGEN SPECIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34248529784     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3280111345     Document Type: Article

References (30)

1. Food JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002; 287:883-889.
2. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
3. Metra M, Giubbini R, Nodari S, Boldi E, ModenaMG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: prospective, randomized, double-blind comparison of the long term. Circulation 2000; 102:546-551.
4. Abraham WT. Beta-blockers: the new standard of therapy for mild heart failure. Arch Intern Med 2000; 160:1237-1247.
5. Van der Does R, Hauf-Zachariou U, Pfarr E, Holtbrugge W, Konig S, Griffiths M, Lahiri A. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol 1999; 83:643-649.
6. Moser M, Frishman W. Results of therapy with carvedilol, a beta-blocker vasodilator antioxidant properties, in hypertensive patients. Am J Hypertens 1998; 11:15S-22S.
7. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, et al., for the US Carvedilol Heart Failure Study Group. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. J Am Coll Cardiol 2001; 37:1692-1699.
8. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357:1385-1390.
9. Juilliere Y. CAPRICORN and COPERNICUS studies. Arch Mal Coeur Vaiss 2002; 95:17-20.
10. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, Clark A. Clinical trial update: CAPRICORN, COPERNICUS, MIRACLE, ST & FRITZ-2, Recover and RENAISSANCE and cachexia and cholesterol in heart failure. Eur J Heart Fail 2001; 3:381-387.
11. Remm WJ. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN): rationale and design. Cardiovasc Drugs Ther 2001; 15:69-77.
12. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol patients with moderate to severe heart failure. The PRECISE trial prospective randomized evaluation of carvedilol on symptoms exercise. Circulation 1996; 94:2793-2799.
13. Ruffolo RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998; 32 (Suppl 1):S22-S30.
14. Feuerstein GZ, Brill A, Ruffolo RR. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997; 80:41L-45L.
15. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest 2001; 120:2035-2046.
16. Grech ED, Dodd NJ, Jackson MJ, Morrison WL, Faragher EB, Ramsdale DR. Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am J Cardiol 1996; 77:122-127.
17. Curello S, Ceconi C, de Giuli F, Panzali AF, Milanesi B, Calarco M, et al. Oxidative stress during reperfusion of human hearts: potential sources of oxygen free radicals. Cardiovasc Res 1995; 29:118-125.
18. Bolli R, Zughaib M, Li XY, Tang XL, Sun JZ, Triana JF, McCay PB. Recurrent ischemia in the canine heart causes recurrent bursts free radical production that have a cumulative effect of contra function. A pathophysiological basis for chronic myocardial 'stunning'. J Clin Invest 1995; 96:1066-1084.
19. Maulik N, Yoshida T, Das DK. Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis. Free Radic Biol Med 1998; 24:869-875.
20. Hasner PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91:1872-1885.
21. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Utsumi H, Nakamura R, et al. Greater susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury. Cardiovasc Res 2001; 49:103-109.
22. Flesch M, Maack C, Cremers B, Baumer AT, Sudkamp M, Bohm M. Effect of beta-blockers on free radical-induced cardiac contraction dysfunction. Circulation 1999; 100:346-353.
23. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicentre Research Group. Am Heart J 1992; 124:41017-41025.
24. Braunwald's Heart Disease, 6th edn. Philadelphia, Pennsylvania: Saunders; 2001. p. 542.
25. Tarpey MM, Fridovich I. Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 2001; 89:224-236.
26. Punchard WA, Kelly FJ, Vladimirov Y. Low level chemiluminescence. free radicals, a practical approach. Oxford: Oxford University Press; 1996. pp. 68-69.
27. Aspee A, Lissi EA. Kinetics and mechanism of the chemiluminescence associated with the free radical-mediated oxidation of amino acids. Luminescence 2000; 15:273-282.
28. Goldhammer E, Shnitzer S, Kleiman N, Abinader EG. Oxygen derived free radicals activity during thrombolysis, assessment by the thermo-chemo- luminescence (TCL) method. Cardiovasc Drugs Ther 1999; 13:30.
29. McNairy M, Gardetto N, Clopton P, Garcia A, Krishnaswamy P, Kazanegra R, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 2002; 143:406-411.
30. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvement in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators. Circulation 1996; 94:2807-2816.